Skip to main content

Table 3 Characteristics after ETV/TDF therapy strategies with the development of abnormal AFP and HCC

From: Effect of potent nucleos(t)ide analog on alpha fetoprotein changes and occurrence of hepatocellular carcinoma in patients with chronic hepatitis B

 

ETV (N = 708)

TDF (N = 339)

P value

HCC

AFP > 20 (ng/mL)

AFP ≤ 20 (ng/mL)

HCC

AFP > 20 (ng/mL)

AFP ≤ 20 (ng/mL)

Patients, n (%)

24 (3.4)

64 (9.0)

620 (87.6)

2 (0.6)

16 (4.7)

321 (94.7)

 

Age, years

53.7 ± 11.4

45.6 ± 11.7

44.8 ± 12.3

62.0 ± 5.7

37.0 ± 8.1

35.6 ± 10.2

 < 0.001

Male, n (%)

20 (83.3)

53 (82.8)

451 (72/7)

1 (50.0)

10 (62.5)

215 (67.0)

0.063

BMI, kg/m2

23.0 (21.0,24.1)

23.3 (22.6,23.9)

22.8 (20.8,24.8)

22.5 (22.5,22.6)

23.4 (22.5,25.0)

22.6 (19.9,24.2)

0.587

History of HBV, years

10 (10,20)

10 (5,20)

10 (6,15)

7.5 (5,10)

20 (12,20)

10 (6.5,20)

0.034

NAFLD, n (%)

2 (8.3)

6 (9.4)

85 (13.7)

0 (0.0)

3 (18.8)

48 (15.0)

0.750

T2DM, n (%)

2 (8.3)

3 (4.7)

29 (4.7)

0 (0.0)

1 (6.3)

10 (3.1)

0.773

Hepatitis B Virology

Log10 HBVDNA, IU/mL

5 (3,6)

5 (4,7)

4 (2,6)

4 (2,5)

5 (3,7)

5 (2,7)

 < 0.001

Log10 HBsAg, IU/mL

3 (2,3)

3 (3,4)

3 (3,4)

3 (3,3)

3 (3,3)

4 (3,5)

 < 0.001

HBeAg-positive, n (%)

11 (45.8)

30 (46.9)

255 (41.1)

0 (0.0)

7 (43.8)

192 (59.8)

 < 0.001

Biochemistry

ALT, U/L

44 (24,68)

84 (45,283)

43 (27,86)

36 (27,44)

100 (48,267)

47 (27,85)

 < 0.001

AST, U/L

56 (33,71)

95 (48,246)

39 (28,67)

37 (32,42)

72 (38,176)

36 (26,69)

 < 0.001

GGT, U/L

51 (33,185)

93 (58,162)

38 (24,78)

36 (31,41)

77 (22,110)

28 (19,56)

 < 0.001

Alkaline phosphatase, U/L

101 (80,145)

109 (82,148)

80 (67,98)

97 (91,103)

81 (62,87)

75 (66,88)

 < 0.001

ALB, U/L

39.1 (30.3,43.3)

41.9 (38.9,44.8)

43.7 (40.9,46.0)

45.7 (44.3,47.0)

41.9 (40.0,44.3)

44.7 (41.7,46.4)

0.100

GLB, U/L

36.0 (29.6,39.5)

31.7 (28.3,37.0)

29.8 (26.7,33.8)

31.9 (27.0,36.7)

29.9 (26.0,33.2)

29.4 (26.8,32.9)

 < 0.001

Total bilirubin, umol/L

21.9 (13.4,38.9)

19.6 (14.1,32.0)

16.5 (12.2,22.0)

11.2 (8.2,14.2)

12.9 (10.8,24.1)

15.3 (11.5,20.2)

 < 0.001

Direct bilirubin, umol/L

6.4 (3.4,12.9)

8.0 (3.9,12.5)

3.6 (2.5,5.5)

2.4 (1.8,3.0)

3.5 (2.1,9.1)

3.1 (2.2,4.5)

 < 0.001

PLT, 10^9/L

114 (77,164)

160 (125,189)

173 (130,217)

116 (71,160)

176 (134,190)

214 (168,255)

 < 0.001

INR

1.11 (1.08,1.14)

1.85 (1.13,2.02)

1.02 (0.96,1.12)

1.53 (1.03,2.02)

1.09 (0.98,1.20)

1.00 (0.95,1.06)

0.774

LSM with SWE, kPa

16.3 (9.5,26.3)

12.9 (7.6,15.5)

7.7 (5.9,13.5)

11.7 (8.1,15.3)

7.3 (4.8,18.1)

6.1 (5.2,9.2)

 < 0.001

AFP, ng/mL

9.6 (2.9,32.8)

46.4 (22.2,214.5)

4.6 (2.7,21.2)

9.8 (4.6,15.0)

18.0 (2.7,118.5)

2.9 (2.1,7.0)

0.002

Cirrhosis, n (%)

23 (95.8)

45 (70.3)

193 (31.1)

2 (100.0)

8 (50.0)

81 (25.2)

 < 0.001

REACH-B score

11.5 ± 3.3

10.5 ± 3.2

8.3 ± 3.5

10.5 ± 0.7

8.4 ± 3.4

7.9 ± 3.1

 < 0.001

Page-B score

17.1 ± 4.1

14.3 ± 4.9

12.7 ± 5.3

17.5 ± 7.8

10.6 ± 5.9

8.9 ± 4.9

 < 0.001

mPage-B score

13.5 ± 3.0

10.4 ± 3.9

9.6 ± 3.7

13.0 ± 4.2

7.6 ± 3.6

6.6 ± 3.4

 < 0.001

aMAP score

60.9 ± 7.2

54.4 ± 9.4

51.3 ± 8.9

60.0 ± 11.3

47.7 ± 7.6

44.2 ± 8.3

 < 0.001

 

Post-hoc

 

1# vs. 2#

1# vs. 3#

1# vs. 4#

1# vs. 5#

1# vs. 6#

2# vs. 3#

2# vs. 4#

2# vs. 5#

2# vs. 6#

3# vs. 4#

3# vs. 5#

3# vs. 6#

4# vs. 5#

4# vs. 6#

5# vs. 6#

Patients, n (%)

               

Age, years

0.003

 < 0.001

0.332

 < 0.001

 < 0.001

0.636

0.049

0.008

 < 0.001

0.037

0.008

 < 0.001

0.004

0.001

0.635

Male, n (%)

               

BMI, kg/m2

               

History of HBV, years

0.043

0.057

0.153

0.704

0.010

0.500

0.430

0.195

0.640

0.355

0.279

0.027

0.215

0.478

0.096

NAFLD, n (%)

               

T2DM, n (%)

               

Hepatitis B Virology

               

Log10 HBVDNA, IU/mL

0.354

0.046

0.406

0.155

0.413

 < 0.001

0.246

0.396

0.724

0.781

0.001

 < 0.001

0.154

0.269

0.265

Log10 HBsAg quantification, IU/mL

0.001

0.006

0.478

0.003

 < 0.001

0.045

0.057

0.629

0.012

0.119

0.114

 < 0.001

0.045

0.016

0.404

HBeAg-positive, n (%)

0.930

0.646

0.207

0.897

0.179

0.375

0.190

0.823

0.056

0.238

0.833

 < 0.001

0.231

0.086

0.202

Biochemistry

               

ALT, U/L

0.001

0.273

0.890

 < 0.001

0.183

 < 0.001

0.189

0.271

 < 0.001

0.637

 < 0.001

0.427

0.095

0.583

0.001

AST, U/L

 < 0.001

0.744

0.778

0.026

0.804

 < 0.001

0.132

0.588

 < 0.001

0.696

0.010

0.827

0.215

0.712

0.009

GGT, U/L

0.922

 < 0.001

0.128

0.128

 < 0.001

 < 0.001

0.126

0.100

 < 0.001

0.685

0.164

0.008

0.393

0.891

0.035

Alkaline phosphatase, U/L

0.001

 < 0.001

0.058

 < 0.001

 < 0.001

 < 0.001

0.421

0.001

 < 0.001

0.697

0.721

0.357

0.625

0.630

0.925

ALB, U/L

               

GLB, U/L

0.053

 < 0.001

0.413

0.008

 < 0.001

0.001

0.855

0.155

0.001

0.678

0.910

0.501

0.723

0.629

0.764

Total bilirubin, umol/L

0.056

0.044

0.291

0.116

0.026

 < 0.001

0.081

 < 0.001

 < 0.001

0.630

0.755

0.448

0.726

0.687

0.928

Direct bilirubin, umol/L

 < 0.001

0.657

0.665

0.768

0.442

 < 0.001

0.079

 < 0.001

 < 0.001

0.752

0.999

0.311

0.766

0.832

0.776

PLT, 10^9/L

0.305

0.065

0.870

0.258

 < 0.001

0.268

0.596

0.683

 < 0.001

0.453

0.888

 < 0.001

0.508

0.172

0.066

INR

               

LSM with SWE, kPa

0.032

 < 0.001

0.151

 < 0.001

 < 0.001

 < 0.001

0.451

0.001

 < 0.001

0.470

0.531

 < 0.001

0.638

0.277

0.103

AFP, ng/mL

0.020

0.988

0.996

0.995

0.987

 < 0.001

0.433

0.045

 < 0.001

0.999

0.996

0.996

0.998

0.999

0.995

Cirrhosis, n (%)

0.011

 < 0.001

0.768

0.001

 < 0.001

 < 0.001

0.361

0.124

 < 0.001

0.036

0.109

0.059

0.180

0.016

0.028

REACH-B score

0.183

 < 0.001

0.674

0.004

 < 0.001

 < 0.001

0.990

0.031

 < 0.001

0.360

0.888

0.104

0.414

0.284

0.565

Page-B score

0.035

 < 0.001

0.915

 < 0.001

 < 0.001

0.018

0.392

0.009

 < 0.001

0.186

0.106

 < 0.001

0.073

0.019

0.222

mPage-B score

0.001

 < 0.001

0.858

 < 0.001

 < 0.001

0.109

0.317

0.006

 < 0.001

0.186

0.028

 < 0.001

0.046

0.012

0.266

aMAP score

0.004

 < 0.001

0.890

 < 0.001

 < 0.001

0.010

0.369

0.007

 < 0.001

0.158

0.108

 < 0.001

0.061

0.011

0.127

  1. Data are median (first quartile, third quartile), n (%), or mean ± SD (standard deviation)
  2. #1- ETV group and HCC occurred during follow-up; 2- ETV group and AFP > 20 (ng/mL) during follow-up; 3- ETV group and AFP ≤ 20 (ng/mL) during follow-up; 4- TDF group and HCC occurred during follow-up; 5- TDF group and AFP > 20 (ng/mL) during follow-up; 6- TDF group and AFP ≤ 20 (ng/mL) during follow-up
  3. ETV entecavir, TDF tenofovir disoproxil fumarate, AFP alpha fetoprotein, HCC hepatic cell carcinoma, BMI body mass index, HBV hepatitis B virus, NAFLD non-alcoholic fatty liver disease, T2DM type 2 diabetes mellitus, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyl transferase, ALB albumin, GLB globulin, TB total bilirubin, DB direct bilirubin, PLT platelet, INR international normalized ratio, SWE shear wave elastography
Back to article page

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us